Direxion Daily Pharmaceutical & Medical Bull 3X Shares ETF PILL
16.03 USD +0.85 (+5.60%)
Nov 9, 2026, 11:36 AM EST
15.24 Day range 16.33
8.28 52-week range 24.15
- YTD
- +30.33%
- 1 year
- +97.90%
- Market cap
- 31.47M
- EPS (ttm)
- 0.873814
- P/E ratio
- 18.34
- YTD return
- +30.33%
- 1-year return
- +97.90%
- Volume
- 83.26K
- Avg volume
- 53.38K
- Open
- 15.80
- Previous close
- 15.18
- Day's range
- 15.24 – 16.33
- 52-week range
- 8.28 – 24.15
5D +1.02 (+6.88%)
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 8.83
- 200-day average
- 7.64
About Direxion Daily Pharmaceutical & Medical Bull 3X Shares ETF
The fund invests at least 80% of its net assets in financial instruments, that, in combination, provide 3X daily leveraged exposure to the index, consistent with the fund's investment objective. The index is a modified equal-weighted index that is designed to measure performance of the stocks comprising the S&P Total Market Index that are classified in the GICS pharmaceuticals sub-industry. The fund is non-diversified.
News
Trump Unveils 'Great Healthcare Plan,' Takes Aim At PBM 'Kickbacks' 
Eli Lilly CEO Slams PBM 'Rent Taking', Says They Drove Insulin List Prices To $275: 'We Can Disintermediate Them Easily' 
Trump's 100% Drug Tariff Will Hit Americans, Economist Says Buyers 'Eat The Cost,' Not Foreign Firms 
Mark Cuban Exposes How Wholesalers Force Pharmacies Into Near-Exclusive Deals, Detailing PBMs' 'Stranglehold' On Drug Pricing 
Mark Cuban Says Cutting PBM Fees Won't Reduce Pharmaceutical R&D Funding: 'Manufacturers Can Sell To Us For More' 
Trump's Pharma Tariffs Can Hit Novo Nordisk, Says Barclays Expert, But It's 'Difficult' To Predict As Drugmakers Have 'Complex Supply Chains' 
Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies 
Mark Cuban Corrects Elizabeth Warren As She Slams JNJ, PFE For Higher Prices And Zero Taxes On Big Pharma: 'PBMs Corrupt Healthcare' 
Trump's Drug Price Order Hits PBMs Hardest: CVS, Cigna, UNH In Focus As Experts Highlight 'Racket,' Pricing Distortion 
Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies
Your note
Sign in to keep a note on PILL — it syncs with the Stock Master app.